GlobeNewswire Inc | Nov 1, 2021 03:00AM EDT

November 01, 2021

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021:

Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15Time: 9:20 AM EST / 2:20 PM GMT

Jefferies London Healthcare Conference Date: Thursday, November 18Time: 3:00 AM EST / 8:00 AM GMT

Piper Sandler 33rd Annual Virtual Healthcare Conference Date: Monday, November 29 Presentation available on-demand starting at 10:00 AM EST / 3:00 PM GMT on Monday, November 22

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Companys website, www.veronapharma.com.

For further information please contact:

US Tel: +1-833-417-0262Verona Pharma plc UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Investor Relations and info@veronapharma.comCommunications Argot Partners Tel: +1-212-600-1902(US Investor Enquiries) verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications Tel: +44 (0)203 950 9144(International Media and European Investor Enquiries) verona@optimumcomms.comMary Clark / Stella Lempidaki / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.